| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(05)17864-7 |
| P698 | PubMed publication ID | 15705456 |
| P2093 | author name string | David J Graham | |
| Wayne A Ray | |||
| Stanford Shoor | |||
| Gerald Levy | |||
| Craig Cheetham | |||
| Rita Hui | |||
| Michele Spence | |||
| David Campen | |||
| P2860 | cites work | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 |
| Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program | Q28165707 | ||
| Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib | Q28191367 | ||
| Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study | Q28192227 | ||
| Nonsteroidal anti-inflammatory drug use and acute myocardial infarction | Q28193035 | ||
| Selective COX-2 inhibition improves endothelial function in coronary artery disease | Q28194726 | ||
| Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial | Q28211435 | ||
| Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction | Q28214120 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons | Q33857146 | ||
| Risk of cardiovascular events associated with selective COX-2 inhibitors | Q34087109 | ||
| Oral erythromycin and the risk of sudden death from cardiac causes | Q34346855 | ||
| Failing the public health--rofecoxib, Merck, and the FDA. | Q34356738 | ||
| Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. | Q34534906 | ||
| Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis | Q38489191 | ||
| Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials | Q41187186 | ||
| Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study | Q42691152 | ||
| Antipsychotics and the risk of sudden cardiac death | Q43817446 | ||
| Association between naproxen use and protection against acute myocardial infarction | Q43999891 | ||
| COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease | Q44182620 | ||
| Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly | Q44316505 | ||
| Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension | Q44642006 | ||
| Cyclic antidepressants and the risk of sudden cardiac death | Q44787230 | ||
| Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults | Q44851038 | ||
| Risk of cardiovascular events and rofecoxib: cumulative meta-analysis | Q45175627 | ||
| Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. | Q45996818 | ||
| The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. | Q55043677 | ||
| Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons | Q68182979 | ||
| Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles | Q71052500 | ||
| Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group | Q73852117 | ||
| P433 | issue | 9458 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| patient | Q181600 | ||
| acute myocardial infarction | Q18558122 | ||
| P304 | page(s) | 475-481 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study | |
| P478 | volume | 365 |
| Q36549016 | "Safe and effective when used as directed": the case of chronic use of opioid analgesics |
| Q47140952 | A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis |
| Q42861082 | A comparative study on the anti-inflammatory effects of single oral doses of naproxen and its hydrogen sulfide (H2S)-releasing derivative ATB-346 in rats with carrageenan-induced synovitis. |
| Q31001545 | A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data |
| Q46050855 | A comparison of the empirical performance of methods for a risk identification system |
| Q30812957 | A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. |
| Q38031932 | A pathway to improved prospective observational post-authorization safety studies |
| Q39240611 | A phase 2 study evaluating the efficacy and safety of a novel, proprietary, nano-formulated, lower dose oral diclofenac |
| Q39334010 | A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain |
| Q53708013 | A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa. |
| Q38038881 | A review of the efficacy, safety, and cost-effectiveness of COX-2 inhibitors for Africa and the Middle East region |
| Q37785123 | AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk |
| Q34768089 | Accounting for the increase in NSAID expenditure: substitution or leakage? |
| Q79273482 | Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk |
| Q37987196 | Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain |
| Q34996960 | All-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: a longitudinal study |
| Q28218005 | An economic model of long-term use of celecoxib in patients with osteoarthritis |
| Q35758411 | An evidence-based update on nonsteroidal anti-inflammatory drugs |
| Q28193309 | An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors |
| Q36082925 | Analyzing patterns of drug use in clinical notes for patient safety |
| Q35914408 | Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes |
| Q37809111 | Antiplatelet drug interactions. |
| Q37044230 | Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? |
| Q38161572 | Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity |
| Q28218310 | Balancing the cyclooxygenase portfolio |
| Q34245387 | Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities |
| Q28237079 | Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data |
| Q36399564 | COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs |
| Q28192719 | COX-2 chronology |
| Q38981326 | COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. |
| Q36740041 | COX-2 inhibition: a possible role in the management of prostate cancer? |
| Q82167116 | COX-2 inhibitors |
| Q36441763 | COX-2 inhibitors and the heart: are all coxibs the same? |
| Q37061134 | COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs |
| Q64080713 | CRISPR/Cas9-based liver-derived reporter cells for screening of mPGES-1 inhibitors |
| Q28210559 | Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) |
| Q28191924 | Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance |
| Q37413163 | Cardiovascular effects of noncardiovascular drugs |
| Q45258184 | Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. |
| Q28222097 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib |
| Q34518911 | Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk |
| Q37378099 | Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs |
| Q38090373 | Cardiovascular risk in juvenile idiopathic arthritis |
| Q34247727 | Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis |
| Q44960512 | Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications |
| Q36439704 | Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? |
| Q28298198 | Cardiovascular risk, hypertension, and NSAIDs |
| Q37049698 | Cardiovascular risk, hypertension, and NSAIDs. |
| Q36520638 | Cardiovascular risks of cyclooxygenase inhibition |
| Q35252770 | Cardiovascular safety of celecoxib in acute myocardial infarction patients: a nested case-control study |
| Q28199071 | Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan |
| Q36299969 | Celecoxib and cardiovascular risks |
| Q37643458 | Celecoxib in arthritis: relative risk management profile and implications for patients |
| Q35830941 | Celecoxib pathways: pharmacokinetics and pharmacodynamics |
| Q34584630 | Celecoxib: a review of its use in the management of arthritis and acute pain |
| Q37600036 | Cellular and molecular studies of the effects of a selective COX-2 inhibitor celecoxib in the cardiac cell line H9c2 and their correlation with death mechanisms. |
| Q82790801 | Chemoprevention of bladder cancer |
| Q46084063 | Clinical epidemiology: Archived answers |
| Q36904910 | Clinical pharmacology of celecoxib, a COX-2 selective inhibitor |
| Q34570225 | Clinical pharmacology of etoricoxib |
| Q38614034 | Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect |
| Q34713083 | Clinical use and pharmacological properties of selective COX-2 inhibitors |
| Q36771112 | Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions |
| Q36349740 | Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs |
| Q36913615 | Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy |
| Q38262502 | Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs |
| Q44975072 | Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia |
| Q21254655 | Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351] |
| Q34574741 | Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial |
| Q64241863 | Complex Role for E-Prostanoid 4 Receptors in Hypertension |
| Q34028288 | Conflicts of interest in research-towards a greater transparency. |
| Q45918839 | Convenient synthesis of Ibuprofen and naproxen aminoacyl, dipeptidoyl and ester derivatives. |
| Q51752393 | Coxibs: evolution of prescription's behaviour in France. |
| Q33259369 | Culture-independent analysis of indomethacin-induced alterations in the rat gastrointestinal microbiota |
| Q28212127 | Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? |
| Q34499514 | Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice |
| Q39683930 | Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib |
| Q35827780 | Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships |
| Q44659710 | Design considerations in an active medical product safety monitoring system. |
| Q42368761 | Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach |
| Q38781550 | Developing Treatments for Chronic Kidney Disease in the 21st Century |
| Q36388099 | Diclofenac and acute myocardial infarction in patients with no major risk factors |
| Q34575738 | Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety |
| Q33941101 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study |
| Q41511728 | Discrepancy among observational studies: example of naproxen-associated adverse events |
| Q26999267 | Disease risk score as a confounder summary method: systematic review and recommendations |
| Q28199809 | Do older adults using NSAIDs have a reduced risk of colorectal cancer? |
| Q46485539 | Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? |
| Q36304331 | Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now? |
| Q44525983 | Drug safety special: chasing shadows |
| Q37127789 | Drug safety surveillance in China and other countries: a review and comparison |
| Q28194546 | Drugs for pain management in dentistry |
| Q21245659 | Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial [ISRCTN38432711]. |
| Q80391877 | Economic evaluation of tramadol/paracetamol combination tablets for osteoarthritis pain in the Netherlands |
| Q34557007 | Edible Bird's nest extract as a chondro-protective agent for human chondrocytes isolated from osteoarthritic knee: in vitro study |
| Q21144686 | Educating health professionals about drug and device promotion: advocates' recommendations |
| Q28219713 | Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study |
| Q35769055 | Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. |
| Q45854165 | Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: a multicenter randomized controlled trial |
| Q36965364 | Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons |
| Q35648213 | Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents |
| Q34412582 | Effects of pentosan polysulfate in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled pilot study |
| Q60913184 | Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis |
| Q35846025 | Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells |
| Q37995534 | Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke |
| Q37106691 | Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature |
| Q31061789 | Estimating national drug consumption using data at different points in the pharmaceutical supply chain |
| Q43092771 | Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies. |
| Q34827484 | Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women |
| Q57841032 | Factor analysis improves the selection of prescribing indicators |
| Q57295112 | Frequency and Associations of Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients With a Musculoskeletal Disorder and Hypertension, Heart Failure, or Chronic Kidney Disease |
| Q35613265 | Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness |
| Q46450711 | Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis |
| Q36332332 | Harmful effects of NSAIDs among patients with hypertension and coronary artery disease |
| Q33642614 | HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease |
| Q36523260 | Heart failure induced by non-cardiac drugs |
| Q35190248 | High-fat diet alters prostanoid balance and perfusion in ischemic myocardium of naproxen-treated swine |
| Q55055829 | How the continuity of care document can advance medical research and public health. |
| Q89668675 | Hyaluronic Acid Injections or Oral Nonsteroidal Anti-inflammatory Drugs for Knee Osteoarthritis: Systematic Review and Meta-analysis of Randomized Trials |
| Q34977411 | Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey |
| Q35015406 | Ibuprofen: pharmacology, efficacy and safety |
| Q57825616 | Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study |
| Q36367834 | Improving postapproval drug safety surveillance: getting better information sooner |
| Q80379053 | Inadequate use of preventive strategies in patients receiving NSAIDs |
| Q46456979 | Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme |
| Q81706472 | Increased risk of cardiovascular events with coxibs and NSAIDs |
| Q94437762 | Increased risk of cardiovascular events with coxibs and NSAIDs |
| Q94437765 | Increased risk of cardiovascular events with coxibs and NSAIDs |
| Q46468154 | Increased risk of cardiovascular events with coxibs and NSAIDs. |
| Q37669375 | Increased risk of endotracheal intubation and heart failure following acute myocardial infarction in patients with urolithiasis: a nationwide population-based study |
| Q28218432 | Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs |
| Q37395368 | Inflammation and shoulder pain--a perspective on rotator cuff disease, adhesive capsulitis, and osteoarthritis: conservative treatment |
| Q82907101 | Inhibition of human neuroblastoma in SCID mice by low-dose of selective Cox-2 inhibitor nimesulide |
| Q42574095 | Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer |
| Q39412555 | Is Cardioprotection Dead? |
| Q28387103 | Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study |
| Q28196511 | Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? |
| Q64895914 | Kounis syndrome triggered by diclofenac sodium injection which leads to myocardial infarction and cardiac arrest. |
| Q36982560 | Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal |
| Q24816136 | Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population |
| Q46977843 | Lovastatin induces the expression of bradykinin type 2 receptors in cultured human coronary artery endothelial cells |
| Q34667577 | Low-intensity electromagnetic millimeter waves for pain therapy |
| Q37173212 | Management of chronic nonmalignant pain with nonsteroidal antiinflammatory drugs. Joint opinion statement of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy |
| Q34555565 | Marketing, media, wishful thinking, and conflicts of interest: inflating the value of new medical technology |
| Q33886458 | Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models |
| Q35005089 | Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition |
| Q38293085 | Medication use evaluation: pharmacist rubric for performance improvement |
| Q88551807 | Medicines Information and the Regulation of the Promotion of Pharmaceuticals |
| Q36404975 | Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? |
| Q34460330 | Minimal impact urethroplasty allows same-day surgery in most patients. |
| Q24621123 | Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen |
| Q26797207 | Molecular cancer prevention: Current status and future directions |
| Q34589334 | Myocardial Infarction and Its Association with the Use of Nonselective NSAIDs: A Nested Case-Control and Time-to-Event Analysis. |
| Q38101544 | Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies |
| Q43257805 | NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib |
| Q26784322 | NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species |
| Q33913113 | Naproxen aggravates doxorubicin-induced cardiomyopathy in rats |
| Q45331959 | National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. |
| Q87015681 | New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction? |
| Q38693695 | Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Acute Myocardial Infarction in the General German Population: A Nested Case-Control Study |
| Q36013803 | Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials |
| Q28196509 | Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction |
| Q37133897 | Nonsteroidal anti-inflammatory drugs and the heart: what is the danger? |
| Q57072074 | Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice |
| Q36479456 | Nonsteroidal anti-inflammatory drugs in the treatment of low back pain |
| Q28681788 | Novel data-mining methodologies for adverse drug event discovery and analysis |
| Q34165083 | Of sophists and spin-doctors: industry-sponsored ghostwriting and the crisis of academic medicine |
| Q37716995 | On the joint use of propensity and prognostic scores in estimation of the average treatment effect on the treated: a simulation study |
| Q38976134 | Oxidative stress and inflammation: liver responses and adaptations to acute and regular exercise |
| Q79959568 | Painful lessons: COX-2 inhibitors, NSAIDs, and hypertension |
| Q48621601 | Parecoxib - getting to the heart of the matter |
| Q37268085 | Patient perspectives of dabigatran: analysis of online discussion forums. |
| Q35641726 | Patients with knee osteoarthritis undergoing total knee arthroplasty have a lower risk of subsequent severe cardiovascular events: propensity score and instrumental variable analysis |
| Q53086602 | Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. |
| Q52349399 | Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview. |
| Q35164718 | PharmGKB summary: ibuprofen pathways. |
| Q43148165 | Pharmacokinetic comparison of an oral diclofenac potassium liquid-filled soft gelatin capsule with a diclofenac potassium tablet |
| Q39360102 | Pharmacological treatment of osteoarthritis in the elderly |
| Q30058397 | Pharmacovigilance Using Clinical Notes |
| Q40736061 | Pharmacovigilance in Germany : It is about time |
| Q47112923 | Pharmacy Student Facilitation of Reporting of Adverse Drug Reactions in a Hospital. |
| Q46689117 | Possible arrhythmiogenic mechanism produced by ibuprofen |
| Q43289071 | Preparation and evaluation of celecoxib-loaded microcapsules with self-microemulsifying core |
| Q33950091 | Prescriptions involving analgesic drugs at a secondary health facility in ibadan, Nigeria |
| Q80207390 | Prevention of hepatitis C in Japan: a lesson for us all |
| Q28200571 | Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks |
| Q89213312 | Product safety spillovers and market viability for biologic drugs |
| Q34080404 | Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute exicitotoxicity in young and old mice |
| Q40145274 | Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells |
| Q43289683 | Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo |
| Q33987564 | Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients |
| Q38870437 | Quasi-experimental study designs series-paper 5: a checklist for classifying studies evaluating the effects on health interventions-a taxonomy without labels |
| Q64890992 | RT-ABCDE strategy for management and prevention of human diseases. |
| Q33989306 | Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety. |
| Q40073885 | Rates of Nonsteroidal Anti-Inflammatory Drug Use in Patients with Established Cardiovascular Disease: A Retrospective, Cross-Sectional Study from NHANES 2009-2010. |
| Q37230245 | Regular use of traditional analgesics predicts major coronary events: A cohort study. |
| Q26849624 | Regulation of genes in the arachidonic acid metabolic pathway by RNA processing and RNA-mediated mechanisms |
| Q85012028 | Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows? |
| Q38457032 | Reinstitutionalizing transparency at Health Canada |
| Q37065707 | Rethinking statistical approaches to evaluating drug safety |
| Q36389468 | Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? |
| Q37178937 | Review of the cardiovascular safety of COXIBs compared to NSAIDS. |
| Q30558799 | Revision rates in journal publications on joint prostheses with noticeably high failure rates in register data sets |
| Q57767701 | Risikoabschätzung in der Schmerztherapie |
| Q28551188 | Risk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias Tool |
| Q58085152 | Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project |
| Q43508335 | Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications |
| Q30234512 | Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data |
| Q28200524 | Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis |
| Q54920356 | Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. |
| Q58666641 | Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: A class effect? |
| Q34479379 | Risk of hyperkalemia associated with selective COX‐2 inhibitors |
| Q46668658 | Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis |
| Q43540832 | Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study |
| Q57751622 | Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis |
| Q34148370 | Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evi |
| Q36600810 | Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. |
| Q81377025 | Risky business |
| Q43161176 | Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study |
| Q64242221 | Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion |
| Q28217943 | Role of the cyclooxygenase pathway in the protection against postischemic stunning in conscious sheep |
| Q30629677 | Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks |
| Q36645806 | Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? |
| Q46202876 | Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation. |
| Q36178468 | Selective cyclooxygenase 2 inhibitors and cardiovascular events |
| Q37294580 | Selective inhibition of prostacyclin synthase activity by rofecoxib |
| Q37394555 | Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model |
| Q37096704 | Should Canada allow direct-to-consumer advertising of prescription drugs?: no. |
| Q36112418 | Soccer and Sudden Cardiac Death in Young Competitive Athletes: A Review |
| Q81718312 | Strong medicine |
| Q37812310 | Study designs in paediatric pharmacoepidemiology |
| Q30423875 | Sulforaphane inhibits prostaglandin E2 synthesis by suppressing microsomal prostaglandin E synthase 1. |
| Q90477834 | Synthesis, Characterization, and Biodistribution of Quantum Dot-Celecoxib Conjugate in Mouse Paw Edema Model |
| Q36360540 | Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? |
| Q37807147 | Systemic Lupus Erythematosus: Safe and Effective Management in Primary Care |
| Q35075939 | Systems pharmacology augments drug safety surveillance |
| Q44627113 | Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk |
| Q36661111 | The CADEUS study: methods and logistics. |
| Q37148157 | The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer |
| Q28222253 | The David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environment |
| Q36831286 | The Effect of Gabapentin Plus Celecoxib on Pain and Associated Complications After Laminectomy |
| Q37196468 | The Effect of Helicobacter pylori on Epidermal Growth Factor Receptor-Induced Signal Transduction and the Preventive Effect of Celecoxib in Gastric Cancer Cells |
| Q43235184 | The FDA: A tough tonic |
| Q37099064 | The association between nonsteroidal anti-inflammatory drugs and potassium concentrations: A pharmacoepidemiological study in Saudi Arabia |
| Q40377176 | The cardiovascular safety of celecoxib |
| Q33239303 | The chrondoprotective actions of a natural product are associated with the activation of IGF-1 production by human chondrocytes despite the presence of IL-1beta |
| Q35773100 | The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction |
| Q28219195 | The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks |
| Q35827761 | The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland |
| Q36419349 | The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production |
| Q30791071 | The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data |
| Q53054239 | The inverse benefit law: how drug marketing undermines patient safety and public health. |
| Q46668679 | The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people |
| Q36411163 | The pharmacotherapy of chronic pain: a review |
| Q37049693 | The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis |
| Q37154872 | The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis |
| Q37268786 | The relation between total joint arthroplasty and risk for serious cardiovascular events in patients with moderate-severe osteoarthritis: propensity score matched landmark analysis |
| Q35234704 | The role of COX-2 in intestinal inflammation and colorectal cancer |
| Q34419629 | The role of inflammation in inflammatory breast cancer. |
| Q36543259 | The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis |
| Q33297001 | The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction |
| Q43283416 | The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada |
| Q28210177 | Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature |
| Q56060521 | Treatment of rheumatoid arthritis |
| Q28475531 | Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale |
| Q58974791 | Unbalanced regulation of over-the-counter analgesics: the lesser of two evils? |
| Q43159534 | Unbalanced reporting of benefits and harms in abstracts on rofecoxib |
| Q42289365 | Understanding Users in the 'Field' of Medications |
| Q34546560 | Understanding the NSAID related risk of vascular events |
| Q28199775 | Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases |
| Q30982556 | Use of data mining at the Food and Drug Administration |
| Q33906348 | Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community |
| Q38409156 | Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study. |
| Q36579891 | Using recovery modalities between training sessions in elite athletes: does it help? |
| Q37290137 | Using technology to promote gastrointestinal outcomes research: a case for electronic health records |
| Q34027269 | Vitamin D metabolism and action in the prostate: implications for health and disease |
| Q46569978 | Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? |
| Q28732492 | Why we need easy access to all data from all clinical trials and how to accomplish it |
| Q94601377 | [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?] |
| Q84600034 | [Current therapeutic approach osteoarthritis] |
| Q82930983 | [NSAIDs and COX-2-inhibitors: current status] |
| Q94601375 | [What do we know about the cardiovascular toxicity of the NSAIDs?] |
| Q46224128 | Le Canada devrait-il autoriser la publicité directe des médicaments d’ordonnance?: NON. |
Search more.